Bio-Techne shareholders vote to adopt Merck KGaA acquisition agreement at special meeting
TECH•Closing still expected later
Closing remains targeted for late 2026 or early 2027, subject to remaining customary conditions and regulatory clearances.
Shareholders approve merger agreement
Bio-Techne held a special shareholder meeting today to vote on its merger agreement with Merck KGaA, Darmstadt, Germany.
Shareholders approved and adopted the definitive merger agreement; the acquisition itself has not yet closed.
